Mathew P - Search Results

1

Prison inmates and palliative care.

Lin J, Mathew P. Lin J, et al. Among authors: mathew p. JAMA. 2007 Dec 5;298(21):2481; author reply 2481. doi: 10.1001/jama.298.21.2481-a. JAMA. 2007. PMID: 18056900 No abstract available.

2

Cancer pain management in prisons: a survey of primary care practitioners and inmates.

Lin JT, Mathew P. Lin JT, et al. Among authors: mathew p. J Pain Symptom Manage. 2005 May;29(5):466-73. doi: 10.1016/j.jpainsymman.2004.08.015. J Pain Symptom Manage. 2005. PMID: 15904749

3

Cancer in an incarcerated population.

Mathew P, Elting L, Cooksley C, Owen S, Lin J. Mathew P, et al. Cancer. 2005 Nov 15;104(10):2197-204. doi: 10.1002/cncr.21468. Cancer. 2005. PMID: 16206295

4

Subcutaneous methadone in terminally ill patients: manageable local toxicity.

Mathew P, Storey P. Mathew P, et al. J Pain Symptom Manage. 1999 Jul;18(1):49-52. doi: 10.1016/s0885-3924(99)00020-2. J Pain Symptom Manage. 1999. PMID: 10439572

5

Mediastinal atypical carcinoid and neurofibromatosis type 1.

Mathew P, Roberts JA, Zwischenberger J, Haque AK. Mathew P, et al. Arch Pathol Lab Med. 2000 Feb;124(2):319-21. doi: 10.5858/2000-124-0319-MACANT. Arch Pathol Lab Med. 2000. PMID: 10656749

6

Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.

Ren W, Joshi R, Mathew P. Ren W, et al. Among authors: mathew p. Mol Cancer Res. 2016 Dec;14(12):1176-1181. doi: 10.1158/1541-7786.MCR-16-0202. Epub 2016 Sep 2. Mol Cancer Res. 2016. PMID: 27590631

7

Qualitative and quantitative variations in liver function thresholds among clinical trials in cancer: a need for harmonization.

Wang E, Song F, Paulus JK, Hackenyos D, Mathew P. Wang E, et al. Among authors: mathew p. Cancer Chemother Pharmacol. 2019 Jul;84(1):213-216. doi: 10.1007/s00280-019-03821-6. Epub 2019 Apr 22. Cancer Chemother Pharmacol. 2019. PMID: 31011815

8

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.

Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Mathew P, et al. Clin Cancer Res. 2007 Oct 1;13(19):5816-24. doi: 10.1158/1078-0432.CCR-07-1269. Clin Cancer Res. 2007. PMID: 17908974 Clinical Trial.

9

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Tannir N, et al. Among authors: mathew p. Cancer. 2006 Aug 1;107(3):497-505. doi: 10.1002/cncr.22038. Cancer. 2006. PMID: 16795067 Clinical Trial.

10

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Kim SJ, et al. Among authors: mathew p. J Natl Cancer Inst. 2006 Jun 7;98(11):783-93. doi: 10.1093/jnci/djj211. J Natl Cancer Inst. 2006. PMID: 16757703

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results